Anti-inflammatory agent 35

Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS) -induced acute lung injury (ALI) in vivo[1].

Product Specifications

CAS Number

[2293951-00-3]

UNSPSC

12352005

Target

ERK; Interleukin Related; NF-κB; p38 MAPK; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/anti-inflammatory-agent-35.html

Purity

99.77

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC(OC1=CC=C(/C=C/C(N2C(/C(CCC2)=C/C3=CC(OC)=C(OC)C(OC)=C3)=O)=O)C=C1OC)=O

Molecular Formula

C27H29NO8

Molecular Weight

495.52

References & Citations

[1]Qian J, et al. Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) . Eur J Med Chem. 2019 Apr 1;167:414-425.